SA521421882B1 - نظم، وطرق وجهاز لتمديد مجموعة من الخلايا - Google Patents

نظم، وطرق وجهاز لتمديد مجموعة من الخلايا

Info

Publication number
SA521421882B1
SA521421882B1 SA521421882A SA521421882A SA521421882B1 SA 521421882 B1 SA521421882 B1 SA 521421882B1 SA 521421882 A SA521421882 A SA 521421882A SA 521421882 A SA521421882 A SA 521421882A SA 521421882 B1 SA521421882 B1 SA 521421882B1
Authority
SA
Saudi Arabia
Prior art keywords
cells
population
expanding
kits
methods
Prior art date
Application number
SA521421882A
Other languages
Arabic (ar)
English (en)
Inventor
ستيمبيرجير كريستيان
جيرميروث لوثار
Original Assignee
جونو ثيرابيوتكس جي إم بي اتش
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by جونو ثيرابيوتكس جي إم بي اتش filed Critical جونو ثيرابيوتكس جي إم بي اتش
Publication of SA521421882B1 publication Critical patent/SA521421882B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48—Automatic or computerized control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
    • C12N2537/10—Cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Sustainable Development (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Computer Hardware Design (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physics & Mathematics (AREA)
SA521421882A 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا SA521421882B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980506P 2014-04-16 2014-04-16
PCT/EP2015/058339 WO2015158868A2 (en) 2014-04-16 2015-04-16 Methods, kits and apparatus for expanding a population of cells

Publications (1)

Publication Number Publication Date
SA521421882B1 true SA521421882B1 (ar) 2023-11-19

Family

ID=53052805

Family Applications (3)

Application Number Title Priority Date Filing Date
SA521421882A SA521421882B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
SA520412247A SA520412247B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
SA516380090A SA516380090B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا

Family Applications After (2)

Application Number Title Priority Date Filing Date
SA520412247A SA520412247B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
SA516380090A SA516380090B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا

Country Status (27)

Country Link
US (2) US11274278B2 (enExample)
EP (2) EP3988920A1 (enExample)
JP (4) JP6696969B2 (enExample)
KR (2) KR102459384B1 (enExample)
CN (3) CN106414724A (enExample)
AU (2) AU2015248786B2 (enExample)
BR (1) BR112016024072B1 (enExample)
CA (2) CA3176848A1 (enExample)
CY (1) CY1124717T1 (enExample)
DK (1) DK3132247T3 (enExample)
ES (1) ES2892927T3 (enExample)
HR (1) HRP20211430T1 (enExample)
HU (1) HUE056852T2 (enExample)
IL (3) IL293587B2 (enExample)
LT (1) LT3132247T (enExample)
MX (2) MX380519B (enExample)
MY (1) MY184699A (enExample)
PH (2) PH12016502017B1 (enExample)
PL (1) PL3132247T3 (enExample)
PT (1) PT3132247T (enExample)
RS (1) RS62471B1 (enExample)
RU (2) RU2020133435A (enExample)
SA (3) SA521421882B1 (enExample)
SG (2) SG11201608557UA (enExample)
SI (1) SI3132247T1 (enExample)
SM (1) SMT202100600T1 (enExample)
WO (1) WO2015158868A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
SG11201608557UA (en) 2014-04-16 2016-11-29 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
KR20180108567A (ko) 2015-10-22 2018-10-04 주노 테라퓨틱스 게엠베하 형질도입을 위한 방법, 키트, 제제 및 장치
MA45488A (fr) * 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
CN107129988A (zh) * 2016-02-29 2017-09-05 广西医科大学 一种特异性结合cd3的核酸适配体及其筛选方法和应用
BR112018073909A2 (pt) * 2016-06-02 2019-02-26 Klotho Therapeutics, Inc. proteínas klotho recombinantes terapêuticas e composições e métodos envolvendo as mesmas
AU2017301887A1 (en) 2016-07-29 2019-02-07 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-CD19 antibodies
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
CN110249046A (zh) * 2016-12-05 2019-09-17 朱诺治疗学股份有限公司 用于过继细胞疗法的工程化细胞的产生
US11624046B2 (en) * 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) * 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) * 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
IL270142B2 (en) * 2017-04-27 2025-05-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
WO2019089855A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
MX2020006297A (es) * 2017-12-15 2020-12-07 Aleta Biotherapeutics Inc Variantes de cd19.
CN107904278B (zh) * 2017-12-25 2021-07-20 北昊干细胞与再生医学研究院有限公司 检测药物对细胞增殖影响的方法
US11149244B2 (en) * 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
CN112424342A (zh) * 2018-05-08 2021-02-26 生命科技公司 用于培养和扩增细胞的组合物和方法
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
JP7495409B2 (ja) 2018-09-11 2024-06-04 ドイチェス クレブスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェンレヒツ 改善された抗ｆｌｔ３抗原結合タンパク質
EP3623383A1 (en) 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
WO2020068840A1 (en) * 2018-09-24 2020-04-02 Southwest Research Institute Three-dimensional bioreactors
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备
KR20200132147A (ko) * 2019-05-15 2020-11-25 의료법인 성광의료재단 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법
EP3978925A4 (en) * 2019-05-24 2023-06-28 Sol Bio Corporation Affinity separation system and method using switch-like adhesion reaction
AU2020287882A1 (en) * 2019-06-07 2022-01-20 Juno Therapeutics, Inc. Automated T cell culture
KR20220101641A (ko) 2019-10-30 2022-07-19 주노 테라퓨틱스 게엠베하 세포 선택 및/또는 자극 장치 및 사용 방법
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
CA3163897A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
JP7751577B2 (ja) 2019-12-06 2025-10-08 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
AU2021213439B2 (en) 2020-01-31 2023-01-05 Cell.Copedia GmbH Methods of isolating a biological entity
JP2023519098A (ja) 2020-02-12 2023-05-10 ジュノー セラピューティクス インコーポレイテッド Ｃｄ１９指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
IL295381A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
KR20230095918A (ko) 2020-08-05 2023-06-29 주노 쎄러퓨티크스 인코퍼레이티드 Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
KR20230090367A (ko) 2020-11-04 2023-06-21 주노 쎄러퓨티크스 인코퍼레이티드 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CA3210581A1 (en) 2021-03-22 2022-09-29 Neil HAIG Methods of determining potency of a therapeutic cell composition
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
JP2024525910A (ja) 2021-07-19 2024-07-12 リペアロン イミュノ ゲーエムベーハー 多能性幹細胞から免疫細胞の集団を作製する方法
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
EP4658675A1 (en) 2023-02-03 2025-12-10 C3S2 GmbH Methods for non-viral manufacturing of engineered immune cells
WO2024182516A1 (en) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
CN117448255B (zh) * 2023-09-28 2024-12-31 深圳市龙华区人民医院 S2饲养细胞、制备方法及其应用
WO2025109111A1 (en) * 2023-11-22 2025-05-30 Immudex Aps Immune cell activating multimers
KR102824339B1 (ko) * 2024-07-01 2025-06-26 현대자동차주식회사 배터리 제어 장치 및 그 방법

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
WO1986002077A1 (en) 1984-10-02 1986-04-10 Meade Harry M Production of streptavidin-like polypeptides
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
DK0700430T3 (da) 1993-06-04 2005-08-15 Us Navy Fremgangsmåder til selektivt af stimulere proliferation af T-celler
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
CA2211951A1 (en) 1995-02-09 1996-08-15 University Of Washington Modified-affinity streptavidin
AU5917796A (en) 1995-04-11 1997-04-09 Trustees Of Boston University Streptavidin mutants
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
CA2283716A1 (en) 1997-03-14 1998-09-17 Gabriel O. Reznik Multiflavor streptavidin
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
WO2000043551A1 (en) 1999-01-26 2000-07-27 Cornell Research Foundation, Inc. Determining viral load in double negative t cells
CA2362126C (en) * 1999-02-03 2017-01-17 Amgen Inc. B7rp-1 polypeptides
ES2338405T3 (es) 1999-02-04 2010-05-07 Pluristem Ltd. Metodo y aparato para mantenimiento y expasion de celulas madre hemopoyeticas y/o celulas progenitoras.
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
EP1227321A1 (en) * 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2003074546A2 (de) 2002-03-01 2003-09-12 Erdmann Volker A Streptavidin-bindungspeptid
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
EP1507557A4 (en) 2002-04-23 2006-06-14 Meir Strahilevitz METHODS AND DEVICES FOR TARGETING A SITE IN A MAMMAL AND DETERMINING CHEMICAL SPECIES FROM A MAMMAL
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
EP2359689B1 (en) 2002-09-27 2015-08-26 The General Hospital Corporation Microfluidic device for cell separation and use thereof
AU2004234627A1 (en) 2003-05-02 2004-11-11 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
DK1623017T3 (da) * 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
EP1690090A1 (en) 2003-11-20 2006-08-16 Biosensor Applications Sweden AB (Publ) Mixture of at least two different antibodies specific for predetermined antigens and use of the mixture
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
EP1766400B1 (en) 2004-06-03 2009-04-15 Meso Scale Technologies, LLC Methods for conducting whole blood assays
DK1800136T3 (da) 2004-10-15 2012-03-26 Danisco Us Inc Kompetitiv differentiel screening
WO2006058226A2 (en) * 2004-11-24 2006-06-01 The Trustees Of Boston University Modified dimeric streptavidins and uses thereof
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US7704708B2 (en) * 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
US20090208471A1 (en) 2006-04-07 2009-08-20 Yun Theodore J Isolation and Use of Human Regulatory T Cells
US20070238169A1 (en) * 2006-04-11 2007-10-11 The Board Of Trustees Of The Leland Stanford Junior University Cell sorter and culture system
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
ES2545457T3 (es) 2006-10-17 2015-09-11 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
US8043822B2 (en) 2006-11-02 2011-10-25 Kyowa Medex Co., Ltd. Method of immunoassaying a component to be measured
WO2008140573A2 (en) 2006-11-15 2008-11-20 Invitrogen Dynal As Methods for reversibly binding a biotin compound to a support
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
WO2008118476A2 (en) * 2007-03-26 2008-10-02 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
PL2193199T3 (pl) 2007-08-20 2014-04-30 Nextera As Ekspozycja fagowa pVII
EP3338895B1 (en) 2007-12-07 2022-08-10 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
CA2878025C (en) 2008-01-18 2018-12-11 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
EP3363893B1 (en) 2008-01-29 2021-06-30 Fred Hutchinson Cancer Research Center Identification of cd8+ t cells that are cd161hi and/or il18ralphahi and have rapid drug efflux capacity
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
US20120214187A1 (en) * 2009-11-02 2012-08-23 Ffina Biolutions, Llc Method for Enhancing the Sensitivity of Antibody Based Assays
US20120321665A1 (en) * 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
EP2363501A1 (en) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
WO2012017081A1 (en) 2010-08-06 2012-02-09 Ludwig-Maximilians-Universität München Identification of t cell target antigens
WO2012058627A2 (en) 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
KR101976882B1 (ko) 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
US9023604B2 (en) * 2011-07-18 2015-05-05 Iba Gmbh Method of reversibly staining a target cell
US9353161B2 (en) 2011-09-13 2016-05-31 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
UA114108C2 (uk) * 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
JP6482461B2 (ja) 2012-07-13 2019-03-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 投与に関する形質導入ｔ細胞の適合性の評価方法
PL2884999T3 (pl) 2012-08-20 2021-07-05 Fred Hutchinson Cancer Research Center Sposób i kompozycje do immunoterapii komórkowej
EP2920204B1 (en) 2012-11-16 2019-09-18 IBA GmbH Streptavidin muteins and methods of using them
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
HRP20201906T1 (hr) 2013-12-20 2021-04-02 Fred Hutchinson Cancer Research Center Označene kimerne efektorske molekule i njihovi receptori
FI3888674T3 (fi) 2014-04-07 2024-07-02 Novartis Ag Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria
SG11201608557UA (en) * 2014-04-16 2016-11-29 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US10131876B2 (en) 2014-04-24 2018-11-20 Miltenyi Biotec Gmbh Method for automated generation of genetically modified T cells
EP3738597A1 (en) 2014-04-25 2020-11-18 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
WO2015166049A1 (en) * 2014-04-30 2015-11-05 Iba Gmbh Method of isolating a target cell
IL254817B2 (en) 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
KR20180108567A (ko) 2015-10-22 2018-10-04 주노 테라퓨틱스 게엠베하 형질도입을 위한 방법, 키트, 제제 및 장치
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
IL270142B2 (en) 2017-04-27 2025-05-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备

Also Published As

Publication number Publication date
AU2022200527A1 (en) 2022-02-17
US20170037368A1 (en) 2017-02-09
CA2945889A1 (en) 2015-10-22
DK3132247T3 (da) 2021-10-11
KR102459384B1 (ko) 2022-10-26
KR20170003932A (ko) 2017-01-10
NZ725213A (en) 2021-10-29
US11274278B2 (en) 2022-03-15
CN116656605A (zh) 2023-08-29
IL248360A0 (en) 2016-11-30
AU2015248786B2 (en) 2021-11-04
EP3988920A1 (en) 2022-04-27
SG11201608557UA (en) 2016-11-29
PT3132247T (pt) 2021-11-03
NZ763583A (en) 2021-10-29
PH12016502017A1 (en) 2017-01-09
MY184699A (en) 2021-04-18
LT3132247T (lt) 2021-12-10
KR20220150988A (ko) 2022-11-11
AU2015248786A1 (en) 2016-11-03
NZ763587A (en) 2021-11-26
JP2025060756A (ja) 2025-04-10
RS62471B1 (sr) 2021-11-30
SMT202100600T1 (it) 2021-11-12
HUE056852T2 (hu) 2022-03-28
IL248360B (en) 2021-02-28
IL280738A (en) 2021-03-25
IL293587A (en) 2022-08-01
SA520412247B1 (ar) 2023-12-05
MX2020014089A (es) 2021-07-21
MX2016013493A (es) 2017-05-10
JP2017513524A (ja) 2017-06-01
PL3132247T3 (pl) 2022-01-03
IL293587B1 (en) 2024-10-01
CN111961647A (zh) 2020-11-20
RU2016144724A (ru) 2018-05-18
IL280738B (en) 2022-07-01
RU2016144724A3 (enExample) 2018-12-12
SA516380090B1 (ar) 2021-10-21
HRP20211430T1 (hr) 2021-12-10
AU2022200527B2 (en) 2025-03-27
CN106414724A (zh) 2017-02-15
RU2735640C9 (ru) 2021-02-08
JP6696969B2 (ja) 2020-05-20
AU2022200527B9 (en) 2025-05-08
JP2023062124A (ja) 2023-05-02
US20220195388A1 (en) 2022-06-23
NZ763585A (en) 2021-10-29
SI3132247T1 (sl) 2021-12-31
CY1124717T1 (el) 2022-07-22
EP3132247A2 (en) 2017-02-22
JP2020124210A (ja) 2020-08-20
EP3132247B1 (en) 2021-08-18
JP7762499B2 (ja) 2025-10-30
SG10201808491UA (en) 2018-11-29
CA2945889C (en) 2024-01-09
RU2020133435A (ru) 2020-12-01
WO2015158868A3 (en) 2016-01-28
MX380519B (es) 2025-03-12
WO2015158868A2 (en) 2015-10-22
KR102714469B1 (ko) 2024-10-11
BR112016024072A2 (pt) 2017-10-10
PH12016502017B1 (en) 2017-01-09
BR112016024072B1 (pt) 2021-02-09
RU2735640C2 (ru) 2020-11-05
PH12020551028A1 (en) 2021-06-07
IL293587B2 (en) 2025-02-01
ES2892927T3 (es) 2022-02-07
CA3176848A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
SA521421882B1 (ar) نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
EP4286055A3 (en) Analytical systems and methods for nucleic acid amplification using sample assigning parameters
MX384536B (es) Sistemas y metodos para multiples analisis.
WO2014116851A3 (en) Methods and systems for using a cloud computing environment to share biological related data
GB2525104A (en) Massively parallel single cell analysis
WO2015200893A3 (en) Methods of analyzing nucleic acids from individual cells or cell populations
MX2016016904A (es) Analisis de secuencias de acidos nucleicos.
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
MX344792B (es) Sistemas y métodos para múltiples análisis.
WO2015138497A3 (en) Systems and methods for rapid data analysis
EP4300100A3 (en) Reagent storage in an assay device
EP4397767A3 (en) Microcapsule compositions and methods
BR112016017155A2 (pt) Sistema e dispositivo para geração com alto rendimento de gotículas combinatoriais e métodos de uso
MY170164A (en) Aptamer-based multiplexed assays
EP4513175A3 (en) Optical systems and methods for biological analysis
AU2013252445A8 (en) Assays, methods and apparatus for assessing RNA disruption
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
WO2015035239A3 (en) Reagents and methods for screening mps i, ii, iiia, iiib, iva, vi, and vii
MX2019000592A (es) Dispositivo dispensador de reactivos analiticos liquidos, y kits analiticos y metodos de uso relacionados.
MX2017001134A (es) Composiciones y metodos para la deteccion y analisis de tuberculosis micobacteriana.
HK1220224A1 (zh) 蛋白纯化的新颖方法
EP3557259A3 (en) Methods and arrays for use in the same
MY182547A (en) Polymerase chain reaction detection system
MX2016017048A (es) Inmunoensayo reactivo y colaborativo potenciado por enzimas (ceer) usando citometria de flujo.
MX2018012485A (es) Sistemas y metodos para ensayos para trigliceridos electroquimicos.